CorFlow Therapeutics secures $9.7million

The start-up CorFlow Therapeutics company of Baar has announced it has now secured $9.7 million from private investors in the USA to enable its products to be used in pioneering clinical trials on patients suffering from acute cardial infarction.

It is with this funding, so-called “seed- financing” which helps start-up companies, that the company will able to assure its clinical and regulatory activities in the long term and at the same time finance a clinical study, whereby 40 patients with acute cardiac infarction are to be closely examined.

The technology developed by CorFlow Therapeutics can both recognise and treat  micro-vascular obstructions while the patients themselves are still in the catheter laboratory.

According to information from the company, it is the only one to provide both diagnostic and therapeutic technology in this field.

At present, application for approval is being sort from six clinics specialising in cardio-vascular treatment in Belgium, Germany, the United Kingdom and Switzerland. 

The photograph is for illustrative purposes only.